-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $68

Benzinga·08/14/2026 19:23:01
语音播报
Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $60 to $68.